

Table 1:

Demographic details of NDMM patients separated into short and prolonged progression-free survival to standard multiple myeloma therapy

		No. of Patients (%)		Total
		Short PFS (n=38)	Prolonged PFS (n=77)	115
Age				
	≤60	23 (33.3)	46 (66.7)	69
	≥60	15 (32.6)	31 (67.4)	46
Gender				
	Male	22 (37.9)	36 (62.1)	58
	Female	16 (28.1)	41 (71.9)	57
Race				
	White	31 (34.8)	58 (65.2)	89
	AA black	4 (22.2)	14 (77.8)	18
	Other	3 (37.5)	5 (62.5)	8
Feature				
	Del17p	1 (100)	0 (0)	1
	Amp1q	17 (47.2)	19 (52.8)	36
	t4:14	5 (45.5)	6 (54.5)	11
	t8:14	10 (50.0)	10 (50.0)	20
	t11:14	4 (23.5)	13 (76.5)	17
	t14:16	1 (33.3)	2 (66.7)	3
	t14:20	0 (0)	0 (0)	0
R-ISS				
	Stage I	10 (24.3)	31 (75.6)	41
	Stage II	23 (35.3)	42 (64.6)	65
	Stage III	5 (55.5)	4 (44.4)	9